Synagis

Sanofi, AstraZeneca mark big leap toward filing of RSV drug in 2022, with safety data in hand to challenge Synagis
Sanofi, AstraZeneca mark big leap toward filing of RSV drug in 2022, with safety data in hand to challenge Synagis
Endpoints
Sanofi
AstraZeneca
RSV
clinical trials
nirsevimab
Synagis
Flag link:
AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis
AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis
Endpoints
AstraZeneca
Sobi
Synagis
RSV
Flag link:
The top 10 patent losses of 2015
The top 10 patent losses of 2015
Fierce Pharma
patents
Lantus
Abilify
Copaxone
Neulasta
Tracleer
Namenda
Avodart
Jalyn
Zyvox
Androgel
Synagis
Sanofi
Bristol-Myers Squibb
Otsuka
Teva Pharmaceutical
Amgen
Actelion
Actavis
GSK
Pfizer
AbbVie
AstraZeneca
Flag link:
Virus drugmaker fights pediatricians' new advice
Virus drugmaker fights pediatricians' new advice
Yahoo/AP
MedImmune
premature infants
Synagis
RSV
Flag link:
PDL Settles MedImmune Dispute
PDL Settles MedImmune Dispute
Yahoo/Zacks.com
PDL Biopharma
MedImmune
AstraZeneca
RSV
Synagis
Abbott Laboratories
Flag link:
PDLI's Synagis Lawsuit Invalidated
PDLI's Synagis Lawsuit Invalidated
Yahoo/Zacks.com
Synagis
PDL Biopharma
MedImmune
lawsuits
Abbott Laboratories
Flag link:
Deals to Be Done After AstraZeneca Setback
Deals to Be Done After AstraZeneca Setback
WSJ Online
AstraZeneca
RSV
Cubist Pharmaceuticals
NanoBio
MicroDose Therapeutx
Novavax
Synagis
motavizumab
Alnylam
Flag link:
Synagis' Special Status Under Health Care Reform
Synagis' Special Status Under Health Care Reform
InVivo
RSV
MedImmune
Synagis
AstraZeneca
Flag link:
AstraZeneca Learns the FDA May Have Gotten Wise to Copy-Cat Drugs
AstraZeneca Learns the FDA May Have Gotten Wise to Copy-Cat Drugs
BNET Pharma
AstraZeneca
FDA
copycat drugs
RSV
Synagis
Rezield
Flag link:
MedImmune responds to FDA on pediatric drug
MedImmune responds to FDA on pediatric drug
Bizjournals.com
FDA
MedImmune
Synagis
RSV
Flag link:
PDL BioPharma rises on better-than-seen outlook
PDL BioPharma rises on better-than-seen outlook
Yahoo/AP
PDL Biopharma
Avastin
Synagis
Flag link: